SecBot SecBot
DEFA14A ·Filed Apr 3, 2026

HRMY

Harmony Biosciences Holdings, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed7mo ago SEC0001104659-26-039453
Proxy solicitation materials
Actionable Insight • Neutral

Traders should note that the board elections are routine, but the recent executive changes, including the appointment of a new COO with a substantial equity package, could signal a shift in leadership and strategy. Monitor for any further announcements regarding the company's direction following these changes.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$27.71
T+0 close · Apr 3, 2026 · via day close
Latest settled
+29.92%
T+60 · $36.00
Vs SPY
+16.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $27.71entry
  2. T+1 · 7mo ago −0.32%α −0.39% · $27.62
  3. T+5 · 7mo ago +4.84%α +0.70% · $29.05
  4. T+20 · 7mo ago +17.61%α +8.63% · $32.59
  5. T+60 · 5mo ago +29.92%α +16.45% · $36.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Harmony Biosciences filed a definitive proxy statement (DEFA14A) for its 2026 annual meeting, where shareholders will vote on the election of four Class III directors, ratification of Deloitte as auditors, and an advisory vote on executive compensation. This filing follows a recent 8-K report disclosing executive changes, including the appointment of Peter Anastasiou as COO and board member Troy Ignelzi, while two other directors stepped down. The cross-filing context suggests these board appointments are materializing as part of the proxy fight materials.

Key Financial Metrics

Vote
director election
Meeting
2026-05-14

Key Facts

  • Filed a definitive proxy statement (DEFA14A) for the 2026 annual meeting.
  • Shareholders will vote on the election of four Class III directors: Geno J. Germano, Troy Ignelzi, Ron Philip, and Andreas Wicki, Ph.D.
  • Shareholders will vote on ratifying Deloitte & Touche LLP as the independent registered public accounting firm.
  • Shareholders will vote on a non-binding, advisory vote on the compensation of named executive officers.
  • A recent 8-K filing (Items 5.02, 7.01, 9.01) disclosed the appointment of Peter Anastasiou as COO and board member Troy Ignelzi, while two directors, including Anastasiou and Antonio Gracias, stepped down.
  • The 8-K filing also disclosed Anastasiou's employment agreement with a $600,000 base salary and a $3.7 million equity grant.

Financial Impact

The appointment of a new COO with a $3.7 million equity grant represents a significant compensation commitment, but the proxy statement itself does not disclose new financial data.

dilutioncompensation

Risk Factors

  • The recent executive changes could lead to strategic shifts or internal restructuring.
  • The $3.7 million equity grant for the new COO may lead to shareholder concerns about dilution and executive compensation.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-039453
Document: 0001104659-26-039453-index-headers.html0001104659-26-039453
Document: 0001104659-26-039453-index.html0001104659-26-039453
Document: 0001104659-26-039453.txt0001104659-26-039453

Track record

20 reports on HRMY

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.82% at T+20 after the Jul 16, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $33.21 Now $32.96 −0.75% settles Dec 15
  2. Nov 4, 202612d ago 8-K Bearish 5/10 No price data
  3. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $34.42 Now $32.96 +4.23% settles Dec 3
  4. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.02 Now $32.96 −10.97% settles Dec 2
  5. Oct 30, 202617d ago 8-K/A Neutral 3/10 Entry $37.91 Now $32.96 −13.06% settles Dec 1
  6. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $38.50 Now $32.96 −14.39% settles Nov 25
  7. Oct 13, 20264w ago 8-K Neutral 3/10 Entry $37.03 to $33.55 Now $32.96 −10.99% ▼ −9.40% −5.79% vs SPY
  8. Oct 1, 20266w ago Press Release Neutral 3/10 Entry $39.57 to $38.59 Now $32.96 −16.70% ▼ −2.48% −3.18% vs SPY
  9. Aug 4, 202614w ago 8-K Bullish 7/10 No price data
  10. Aug 4, 202614w ago Press Release Bullish 6/10 Entry $38.78 Now $32.96 −15.01% No price data
Showing 10 of 20

US Market Status

Market Closed · Opens in 7h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026